231 related articles for article (PubMed ID: 2223816)
1. Liposomes for the sustained drug release in vivo.
Blume G; Cevc G
Biochim Biophys Acta; 1990 Nov; 1029(1):91-7. PubMed ID: 2223816
[TBL] [Abstract][Full Text] [Related]
2. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol).
Maruyama K; Yuda T; Okamoto A; Kojima S; Suginaka A; Iwatsuru M
Biochim Biophys Acta; 1992 Sep; 1128(1):44-9. PubMed ID: 1390877
[TBL] [Abstract][Full Text] [Related]
3. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.
Dos Santos N; Mayer LD; Abraham SA; Gallagher RC; Cox KA; Tardi PG; Bally MB
Biochim Biophys Acta; 2002 Apr; 1561(2):188-201. PubMed ID: 11997119
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of the lipid vesicle longevity in vivo.
Blume G; Cevc G
Biochim Biophys Acta; 1993 Mar; 1146(2):157-68. PubMed ID: 8452853
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the in vivo circulation lifetime of L-alpha-distearoylphosphatidylcholine liposomes: importance of liposomal aggregation versus complement opsonization.
Ahl PL; Bhatia SK; Meers P; Roberts P; Stevens R; Dause R; Perkins WR; Janoff AS
Biochim Biophys Acta; 1997 Oct; 1329(2):370-82. PubMed ID: 9371428
[TBL] [Abstract][Full Text] [Related]
6. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target.
Klibanov AL; Maruyama K; Beckerleg AM; Torchilin VP; Huang L
Biochim Biophys Acta; 1991 Feb; 1062(2):142-8. PubMed ID: 2004104
[TBL] [Abstract][Full Text] [Related]
7. Cationic poly(ethyleneglycol) lipids incorporated into pre-formed vesicles enhance binding and uptake to BHK cells.
Fenske DB; Palmer LR; Chen T; Wong KF; Cullis PR
Biochim Biophys Acta; 2001 Jun; 1512(2):259-72. PubMed ID: 11406103
[TBL] [Abstract][Full Text] [Related]
8. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs.
Gabizon AA; Barenholz Y; Bialer M
Pharm Res; 1993 May; 10(5):703-8. PubMed ID: 8321835
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles.
Parr MJ; Ansell SM; Choi LS; Cullis PR
Biochim Biophys Acta; 1994 Oct; 1195(1):21-30. PubMed ID: 7918562
[TBL] [Abstract][Full Text] [Related]
10. Targeted and sustained drug delivery using PEGylated galactosylated liposomes.
Managit C; Kawakami S; Nishikawa M; Yamashita F; Hashida M
Int J Pharm; 2003 Nov; 266(1-2):77-84. PubMed ID: 14559396
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of stealth versus conventional liposomes: effect of dose.
Allen TM; Hansen C
Biochim Biophys Acta; 1991 Sep; 1068(2):133-41. PubMed ID: 1911826
[TBL] [Abstract][Full Text] [Related]
12. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes.
Woodle MC; Matthay KK; Newman MS; Hidayat JE; Collins LR; Redemann C; Martin FJ; Papahadjopoulos D
Biochim Biophys Acta; 1992 Apr; 1105(2):193-200. PubMed ID: 1586658
[TBL] [Abstract][Full Text] [Related]
13. Effects of PEG-lipids on permeability of phosphatidylcholine/cholesterol liposomes in buffer and in human serum.
Silvander M; Johnsson M; Edwards K
Chem Phys Lipids; 1998 Dec; 97(1):15-26. PubMed ID: 10081146
[TBL] [Abstract][Full Text] [Related]
14. Interaction between PEG lipid and DSPE/DSPC phospholipids: An insight of PEGylation degree and kinetics of de-PEGylation.
Paolino D; Accolla ML; Cilurzo F; Cristiano MC; Cosco D; Castelli F; Sarpietro MG; Fresta M; Celia C
Colloids Surf B Biointerfaces; 2017 Jul; 155():266-275. PubMed ID: 28460301
[TBL] [Abstract][Full Text] [Related]
15. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits.
Awasthi VD; Garcia D; Goins BA; Phillips WT
Int J Pharm; 2003 Mar; 253(1-2):121-32. PubMed ID: 12593943
[TBL] [Abstract][Full Text] [Related]
16. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells.
Allen TM; Brandeis E; Hansen CB; Kao GY; Zalipsky S
Biochim Biophys Acta; 1995 Jul; 1237(2):99-108. PubMed ID: 7632714
[TBL] [Abstract][Full Text] [Related]
17. Sterically stabilized liposomes.
Woodle MC; Lasic DD
Biochim Biophys Acta; 1992 Aug; 1113(2):171-99. PubMed ID: 1510996
[TBL] [Abstract][Full Text] [Related]
18. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.
Dadashzadeh S; Mirahmadi N; Babaei MH; Vali AM
J Control Release; 2010 Dec; 148(2):177-86. PubMed ID: 20800629
[TBL] [Abstract][Full Text] [Related]
20. Effect of polyethyleneglycol-phospholipids on aggregate structure in preparations of small unilamellar liposomes.
Edwards K; Johnsson M; Karlsson G; Silvander M
Biophys J; 1997 Jul; 73(1):258-66. PubMed ID: 9199790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
